Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (25313)	2/18/1999 5:18:00 PM
From: Compadre	Read Replies (1) \| Respond to of 120523

Jenna: What do you think of BSX. It has displayed strength in the last couple of days, and it is on a technical breakout. Regards, Jaime

To: Jenna who wrote (25313)	2/18/1999 6:06:00 PM
From: kha vu	Respond to of 120523

Drugs sector...the call options for SEPR strike price 120 for March and April is very good... I did mentioned SEPR on this board about a month ago in conjunction with LIPO and LGND. (disclose: i hold sizable position in all THREE as long term ) here is the news of SEPR concerning its earnings and products: Thursday February 18, 3:13 pm Eastern Time Sepracor soars on robust earnings guidance By Ransdell Pierson NEW YORK, Feb 18 (Reuters) - Sepracor Inc. (Nasdaq:SEPR - news) shares jumped to a new high Thursday after the company, which is now losing money, endorsed a bullish earnings forecast for the years 2001-2003. Chief Financial Officer David Southwell told Reuters that he believed an earnings per share forecast by Morgan Stanley Dean Witter analyst Douglas Lind of $13.48 for the year 2003 was ''conservative.'' Southwell said he agreed with the ''underlying assumptions'' behind Lind's forecast of $5.69 per share for the year 2001 and $10.38 for 2002. Shares of the Massachussetts-based biotech company were up 9-7/16 at 128 on the Nasdaq. The previous intraday high for the company, which specializes in making safer versions of existing drugs, was 121-3/8. ''We think we should be able to do in excess of that ($13.48 per diluted share in 2003). We think that number is conservative,'' said Southwell, reached in London by telephone. Sepracor in 1998 elevated its profile by licensing improved versions of major prescription drugs to three of the country's largest drug makers, Eli Lilly and Co (NYSE:LLY - news), Schering-Plough Corp (NYSE:SGP - news) and Johnson & Johnson (NYSE:JNJ - news). Southwell said his company planned to license out several more drugs in 1999, but declined to identify the compounds or the names of companies with which he is negotiating. He said the drugs were among nine the company hopes to license to other companies for royalties in coming years, all protected by secured or pending patents. He said the drugs would target therapeutic areas now worth $8 billion a year in sales. The compounds include chemically altered versions of the Pfizer Inc (NYSE:PFE - news) hypertension drug Norvasc, the Glaxo Wellcome Plc (quote from Yahoo! UK & Ireland: GLXO.L) asthma drug Serevent and the Johnson & Johnson antifungal Sporanox, Southwell said. Additionally, Southwell said Sepracor hoped to retain full rights to another nine drugs, also improved versions of products developed and now sold by other companies. He said those drugs had a multibillion-dollar annual sales potential and included a version of Pfizer's drug Cardura for treatment of enlarged prostate and of Glaxo's antidepressant Wellbutrin.